MedTrace Logo

A Study of DS-9606a in Patients With Advanced Solid Tumors

NCT05394675 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2026-03-20

No results posted yet for this study

Summary

This study will assess the safety and tolerability of DS-9606a in patients with advanced solid tumors.

Conditions

Interventions

DRUG

DS-9606a

Intravenous infusion

Sponsors & Collaborators

Principal Investigators

  • Clinical Director · Daiichi Sankyo

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-31
Primary Completion
2026-02-06
Completion
2026-02-06
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05394675 on ClinicalTrials.gov